Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 6/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.52 |
| ▸ | NPY4R | P50391 | 4/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391184 | 0.90 | CYP1A2 (0.61) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29603738 | 0.90 | CYP1A2 (0.61) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29356389 | 0.90 | CYP1A2 (0.61) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL28409679 | 0.90 | CYP1A2 (0.61) | CYP1A2GLATSHRNFKB1APEX1 | |
| Hydrochloric Acid SCHEMBL1880117 | 0.87 | CYP1A2 (0.58) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29393341 | 0.86 | SIRT5 (0.64) | CHRM2CHRM4CHRM1NPY1RNPY4R | |
| SCHEMBL1735525 | 0.86 | CYP2C19 (0.65) | CYP1A2GLATSHRNFKB1APEX1 | |
| Acetic Acid SCHEMBL29358131 | 0.86 | NPY1R (0.59) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL29506889 | 0.85 | NOS2 (0.55) | CYP1A2GLATSHRNFKB1APEX1 | |
| SCHEMBL1736266 | 0.85 | NPY1R (0.55) | CYP1A2GLATSHRNFKB1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| US-20220105135-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF OPIOID SIGNALING IN THE TUMOR MICROENVIRONMENT | DANA-FARBER CANCER INSTITUTE, INC. | 2022-04-07 | — | — | US | claimed |
| CN-121081297-A | Liposome for improving stability of dihydroquercetin as well as preparation method and application thereof | 深圳中科欣扬生物科技有限公司 | 2025-12-09 | — | — | CN | disclosed |
| EP-4138793-B1 | NOVEL NON-PROTEINIC FURIN INHIBITOR | UPTION (LU) | 2025-07-02 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-117084982-B | Preparation and application of nano-engineering red blood cells | 中国人民解放军军事科学院军事医学研究院 | 2024-02-09 | — | — | CN | disclosed |
| US-20240041813-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| CN-117084982-A | Preparation and application of nano-engineering red blood cells | 中国人民解放军军事科学院军事医学研究院 | 2023-11-21 | — | — | CN | disclosed |
| US-20230338465-A1 | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases | Vitruviae LLC | 2023-10-26 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4138793-A1 | NOVEL NON-PROTEINIC FURIN INHIBITOR | Uption (LU) | 2023-03-01 | — | — | EP | disclosed |
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4125897-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP Asset V, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666567-A | Furin inhibitors for the treatment of coronavirus infection | BP资产V股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220105135-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF OPIOID SIGNALING IN THE TUMOR MICROENVIRONMENT | DANA-FARBER CANCER INSTITUTE, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2022040436-A2 | FUSION PROTEINS FOR THE DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES | Vitruviae LLC (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041813-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | ELOVL3, ELOVL1, ELOVL5 | CYP1A2 745/4885GLA 1432/4885TSHR 4114/4885 |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | CD44, FCGR3B, FCGR2A | CYP1A2 4822/4885GLA 3893/4885TSHR 754/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CYP1A2 185/4885GLA 219/4885TSHR 1783/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | CYP1A2 1645/4885GLA 77/4885TSHR 3360/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CYP1A2 185/4885GLA 219/4885TSHR 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.